{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:39:25Z","timestamp":1772941165518,"version":"3.50.1"},"reference-count":208,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006730","name":"Romanian Government Ministry of Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007059","name":"Palacky University Olomouc","doi-asserted-by":"publisher","award":["IGA_LF_2024_004"],"award-info":[{"award-number":["IGA_LF_2024_004"]}],"id":[{"id":"10.13039\/501100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"COST","doi-asserted-by":"publisher","award":["CA21116"],"award-info":[{"award-number":["CA21116"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003766","name":"Ministerul Educa\u0163iei Na\u0163ionale","doi-asserted-by":"publisher","award":["23PHE \\u2044 2023"],"award-info":[{"award-number":["23PHE \\u2044 2023"]}],"id":[{"id":"10.13039\/501100003766","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003766","name":"Ministerul Educa\u0163iei Na\u0163ionale","doi-asserted-by":"publisher","award":["PN-IV-P8\\u20138.1-PRE-HE-ORG-2023\\u20130069"],"award-info":[{"award-number":["PN-IV-P8\\u20138.1-PRE-HE-ORG-2023\\u20130069"]}],"id":[{"id":"10.13039\/501100003766","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NW24\\u201303\\u201300024"],"award-info":[{"award-number":["NW24\\u201303\\u201300024"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020668","name":"European Research Executive Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000783","name":"European Research Executive Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006595","name":"Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.semcancer.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:55:46Z","timestamp":1757170546000},"page":"31-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic pancreatic cancer biomarkers and pharmacogenetics"],"prefix":"10.1016","volume":"116","author":[{"given":"Ales","family":"Langer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Soucek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Vymetalkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmeri","family":"Rizzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Bunduc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias P.","family":"Nikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Hlavac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kroupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Farinella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Campa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-2681","authenticated-orcid":false,"given":"Beatrice","family":"Mohelnikova-Duchonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2025.08.002_bib1","unstructured":"J. Ferlay, M. Ervik, M. Lam, M. Laversanne, M. Colombet, L. Mery, et al. (2024) Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer., [cited 08 June 2024]. Available from: \u3008https:\/\/gco.iarc.who.int\/today\u3009."},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdv133","article-title":"A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer","volume":"26","author":"Deplanque","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","article-title":"A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial","volume":"26","author":"Fuchs","year":"2015","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.semcancer.2025.08.002_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.semcancer.2025.08.002_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2025.08.002_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.critrevonc.2015.08.004","article-title":"Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies","volume":"97","author":"Asi\u0107","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17512433.2024.2319340","article-title":"Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives","volume":"17","author":"Toledo","year":"2024","journal-title":"Expert Rev. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.semcancer.2025.08.002_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib10","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4143\/crt.2013.158","article-title":"Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as First-Line chemotherapy in patients with advanced pancreatic cancer","volume":"47","author":"Lim","year":"2015","journal-title":"Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.semcancer.2025.08.002_bib12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.2009.25.4433","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study","volume":"28","author":"Colucci","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.semcancer.2025.08.002_bib13","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113430","article-title":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: the open-label, multicenter, phase II nITRO trial","volume":"196","author":"Melisi","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.08.002_bib15","first-page":"35","article-title":"The search for plant sources of anticancer drugs","volume":"20","author":"Perdue","year":"1969","journal-title":"Morris Arbor. Bull."},{"issue":"9","key":"10.1016\/j.semcancer.2025.08.002_bib16","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. Vi. isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40001-024-01657-2","article-title":"Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties","volume":"29","author":"Sati","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"34","key":"10.1016\/j.semcancer.2025.08.002_bib18","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","article-title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial","volume":"29","author":"Von Hoff","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1073\/pnas.77.3.1561","article-title":"Taxol stabilizes microtubules in mouse fibroblast cells","volume":"77","author":"Schiff","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"20","key":"10.1016\/j.semcancer.2025.08.002_bib20","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1073\/pnas.90.20.9552","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations","volume":"90","author":"Jordan","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"50","key":"10.1016\/j.semcancer.2025.08.002_bib21","doi-asserted-by":"crossref","first-page":"31785","DOI":"10.1016\/S0021-9258(18)31764-2","article-title":"Solution structure of Taxotere-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of the taxol side chain","volume":"269","author":"Andreu","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0006-291X(05)81474-3","article-title":"Effects of taxotere on murine and human tumor cell lines","volume":"187","author":"Riou","year":"1992","journal-title":"Biochem Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib23","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-14-0265","article-title":"Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells","volume":"13","author":"Azarenko","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib24","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1021\/acs.molpharmaceut.9b01221","article-title":"Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer","volume":"17","author":"Yuan","year":"2020","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing neoadjuvant Nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-Negative breast Cancer-The evaluating treatment with neoadjuvant abraxane (ETNA) trial: a randomized phase 3 clinical trial","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/dmd.30.4.438","article-title":"Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship","volume":"30","author":"Cresteil","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1158\/1078-0432.CCR-12-2080","article-title":"Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice","volume":"19","author":"van de Steeg","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.semcancer.2025.08.002_bib30","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.08.002_bib31","article-title":"Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma","volume":"21","author":"Hartley","year":"2020","journal-title":"Pr. Lab Med."},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib32","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e318279b861","article-title":"Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues","volume":"42","author":"Mohelnikova-Duchonova","year":"2013","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00280-013-2246-2","article-title":"The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer","volume":"72","author":"Mohelnikova-Duchonova","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/mutage\/ger075","article-title":"The role of ABC transporters in progression and clinical outcome of colorectal cancer","volume":"27","author":"Hlavata","year":"2012","journal-title":"Mutagenesis"},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2217\/pgs.13.26","article-title":"The expression profile of ATP-binding cassette transporter genes in breast carcinoma","volume":"14","author":"Hlav\u00e1\u010d","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"16","key":"10.1016\/j.semcancer.2025.08.002_bib37","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2217\/pgs.12.165","article-title":"Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity","volume":"13","author":"Jabir","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib38","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1111\/cts.13386","article-title":"CYP2C8*3 and *4 define CYP2C8 phenotype: an approach with the substrate cinitapride","volume":"15","author":"Campod\u00f3nico","year":"2022","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib39","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s10637-022-01275-x","article-title":"Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel","volume":"40","author":"Horiuchi","year":"2022","journal-title":"Invest N. Drugs"},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10549-022-06596-2","article-title":"Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark","volume":"194","author":"Hjorth","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"17","key":"10.1016\/j.semcancer.2025.08.002_bib41","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/cncr.35343","article-title":"Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: a multicenter, prospective, observational cohort study (GENESECT study)","volume":"130","author":"Hatori","year":"2024","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MPA.0000000000002032","article-title":"Class III \u03b2-Tubulin expression is of value in selecting nab -Paclitaxel and gemcitabine as First-Line therapy in unresectable pancreatic cancer","volume":"51","author":"Kato","year":"2022","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2025.08.002_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105585","article-title":"Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin","volume":"168","author":"Barbolina","year":"2021","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib44","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.18632\/oncotarget.6772","article-title":"Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer","volume":"7","author":"Jiang","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/2326-6066.CIR-23-0171","article-title":"EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade","volume":"11","author":"Tabasum","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"15","key":"10.1016\/j.semcancer.2025.08.002_bib46","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/cncr.34269","article-title":"Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer","volume":"128","author":"Yu","year":"2022","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.semcancer.2025.08.002_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153738","article-title":"Gemcitabine plus Nab-Paclitaxel induces PD-L1 mRNA expression in Plasma-Derived microvesicles in pancreatic cancer","volume":"13","author":"Del Re","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib48","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12967-024-04989-z","article-title":"High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study","volume":"22","author":"Huang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.dld.2015.11.001","article-title":"Prognostic and predictive markers in pancreatic adenocarcinoma","volume":"48","author":"Le","year":"2016","journal-title":"Dig. Liver Dis."},{"issue":"10409","key":"10.1016\/j.semcancer.2025.08.002_bib50","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12029-024-01025-7","article-title":"Efficacy of Cisplatin-Containing chemotherapy regimens in patients of pancreatic ductal adenocarcinoma: a systematic review and Meta-analysis","volume":"55","author":"Rehman","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.semcancer.2025.08.002_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221083050","article-title":"Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and fanconi anemia genes","volume":"14","author":"Emelyanova","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"7540","key":"10.1016\/j.semcancer.2025.08.002_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.semcancer.2025.08.002_bib54","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision Medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib55","first-page":"409","article-title":"Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations","volume":"60","author":"Lal","year":"2000","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib56","first-page":"738","article-title":"Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer","volume":"7","author":"Tersmette","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.08.002_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.749490","article-title":"DNA damage repair deficiency in pancreatic ductal adenocarcinoma: preclinical models and clinical perspectives","volume":"9","author":"Stoof","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"7381","key":"10.1016\/j.semcancer.2025.08.002_bib58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2025.08.002_bib59","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231189127","article-title":"Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake","volume":"15","author":"Golan","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00271","article-title":"Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a germline BRCA or PALB2 mutation","author":"Yu","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib61","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/CAD.0000000000000178","article-title":"Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation","volume":"26","author":"Vyas","year":"2015","journal-title":"Anticancer Drugs"},{"issue":"13","key":"10.1016\/j.semcancer.2025.08.002_bib62","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031701","article-title":"Therapeutic targeting of DNA damage response in cancer","volume":"23","author":"Choi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Atlas research network. Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Cancer Genome","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.seminoncol.2018.05.004","article-title":"Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma","volume":"45","author":"Zhen","year":"2018","journal-title":"Semin Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib66","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-Driven precision Medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.08.002_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1282824","article-title":"Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)","volume":"14","author":"Pervin","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.semcancer.2025.08.002_bib68","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211014818","article-title":"The role of PARP inhibitors in BRCA mutated pancreatic cancer","volume":"14","author":"Chi","year":"2021","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14040897","article-title":"Precision Medicine for BRCA\/PALB2-Mutated pancreatic cancer and emerging strategies to improve therapeutic responses to PARP inhibition","volume":"14","author":"Principe","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2025.08.002_bib70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fonc.2018.00016","article-title":"Role of BRCA mutations in the modulation of response to platinum therapy","volume":"8","author":"Mylavarapu","year":"2018","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib71","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib72","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14796694.2025.2458458","article-title":"A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)","volume":"21","author":"Wainberg","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib73","doi-asserted-by":"crossref","unstructured":"Dixon-Hughes J. PRIMUS002: A study looking at two neo-adjuvant chemotherapy treatments for pancreatic cancer in patients whose cancer is able to be operated on. doi:10.1186\/ISRCTN34129115.","DOI":"10.1186\/ISRCTN34129115"},{"issue":"9","key":"10.1016\/j.semcancer.2025.08.002_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094709","article-title":"Beyond BRCA: the emerging significance of DNA damage response and personalized treatment in pancreatic and prostate cancer patients","volume":"23","author":"Dalmasso","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.semcancer.2025.08.002_bib75","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","article-title":"Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX","volume":"24","author":"Sehdev","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib76","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.21037\/jgo.2019.09.12","article-title":"DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer","volume":"10","author":"Palacio","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib77","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40265-020-01304-0","article-title":"New treatment strategies for metastatic pancreatic ductal adenocarcinoma","volume":"80","author":"Singh","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010217","article-title":"The impact of biomarkers in pancreatic ductal adenocarcinoma on diagnosis, surveillance and therapy","volume":"14","author":"Sturm","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib79","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/gutjnl-2019-319984","article-title":"DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives","volume":"70","author":"Perkhofer","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2025.08.002_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211033704","article-title":"Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX","volume":"13","author":"van der Sijde","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv132","article-title":"Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma","volume":"107","author":"Capello","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajpath.2018.10.004","article-title":"Pancreatic ductal adenocarcinoma and its precursor lesions: histopathology, cytopathology, and molecular pathology","volume":"189","author":"Ren","year":"2019","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020397","article-title":"Evaluating pancreatic and biliary neoplasms with small Biopsy-Based next generation sequencing (NGS): doing more with less","volume":"14","author":"Nikas","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib84","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00092","article-title":"Clinical utility of tumor Next-Generation sequencing panel testing to inform treatment decisions for patients with advanced solid tumors in a tertiary care center","author":"Bogdan","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib85","article-title":"Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the \"MOZART\" prospective observational study","author":"Schettini","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189065","article-title":"Breaking the stromal barrier in pancreatic cancer: advances and challenges","volume":"1879","author":"Chakkera","year":"2024","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib87","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cncy.22533","article-title":"Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB","volume":"130","author":"Gan","year":"2022","journal-title":"Cancer Cytopathol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib88","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/PPO.0b013e31827459b6","article-title":"Pathology and molecular genetics of pancreatic neoplasms","volume":"18","author":"Wood","year":"2012","journal-title":"Cancer J."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"NPJ Precis Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib90","first-page":"2969","article-title":"Progression model for pancreatic cancer","volume":"6","author":"Hruban","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib91","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s10620-023-07904-6","article-title":"Pancreatic cancer biomarkers: oncogenic mutations, tissue and liquid biopsies, and Radiomics-A review","volume":"68","author":"Amaral","year":"2023","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib92","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When should we order a next generation sequencing test in a patient with cancer?","volume":"25","author":"Colomer","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib94","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/bjs\/znac272","article-title":"Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study","volume":"109","author":"Suurmeijer","year":"2022","journal-title":"Br. J. Surg."},{"issue":"18","key":"10.1016\/j.semcancer.2025.08.002_bib95","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 expression distinguishes classical and Basal-like subtypes in advanced pancreatic cancer","volume":"26","author":"O'Kane","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1-3","key":"10.1016\/j.semcancer.2025.08.002_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17474124.2024.2322648","article-title":"Next-generation therapies for pancreatic cancer","volume":"18","author":"Buckley","year":"2024","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"13","key":"10.1016\/j.semcancer.2025.08.002_bib97","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib98","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.semcancer.2025.08.002_bib99","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discov."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib101","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging all KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28083615","article-title":"Multiple strategies to develop small molecular KRAS directly bound inhibitors","volume":"28","author":"Zhou","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib103","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1541-7786.MCR-22-0626","article-title":"BRAF-Driven pancreatic cancer: prevalence, molecular features, and therapeutic opportunities","volume":"21","author":"Ciner","year":"2023","journal-title":"Mol. Cancer Res."},{"issue":"22","key":"10.1016\/j.semcancer.2025.08.002_bib104","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1158\/1078-0432.CCR-22-3930","article-title":"Oncogenic drivers and therapeutic vulnerabilities in KRAS Wild-Type pancreatic cancer","volume":"29","author":"Singh","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"7035","key":"10.1016\/j.semcancer.2025.08.002_bib105","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib106","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2025.08.002_bib107","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/CMAR.S211151","article-title":"BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects","volume":"12","author":"Wong","year":"2020","journal-title":"Cancer Manag Res."},{"key":"10.1016\/j.semcancer.2025.08.002_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102650","article-title":"Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: still looking through a dirty glass window?","volume":"121","author":"Incorvaia","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib109","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.17140\/POJ-3-e011","article-title":"PARP inhibitors in pancreatic cancer: from phase I to plenary session","volume":"3","author":"Patel","year":"2019","journal-title":"Pancreas"},{"issue":"23","key":"10.1016\/j.semcancer.2025.08.002_bib110","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence Meta-Analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.semcancer.2025.08.002_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215240","article-title":"TRAIL receptor targeting agents potentiate PARP inhibitor efficacy in pancreatic cancer independently of BRCA2 mutation status","volume":"14","author":"Ben Khaled","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib112","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib113","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib114","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib115","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/cncr.31218","article-title":"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma","volume":"124","author":"O\u2032Reilly","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib116","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12929-022-00870-7","article-title":"Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors","volume":"29","author":"Chu","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib117","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-Mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.semcancer.2025.08.002_bib118","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-Mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib119","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/bjc.2017.40","article-title":"BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer","volume":"116","author":"Pishvaian","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"42","key":"10.1016\/j.semcancer.2025.08.002_bib120","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib121","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI70196","article-title":"BRCA1185delAG tumors May acquire therapy resistance through expression of RING-less BRCA1","volume":"126","author":"Drost","year":"2016","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib122","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib123","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw148","article-title":"Mechanisms of therapy resistance in Patient-Derived xenograft models of BRCA1-Deficient breast cancer","volume":"108","author":"Ter Brugge","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib124","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acsmedchemlett.2c00063","article-title":"Identification of RAD51-BRCA2 inhibitors using N-Acylhydrazone-Based dynamic combinatorial chemistry","volume":"13","author":"Bagnolini","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"16_","key":"10.1016\/j.semcancer.2025.08.002_bib125","article-title":"Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1\/2+) pathogenic variants: SWOG S2001","volume":"41","author":"Chung","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib126","first-page":"236","article-title":"Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells","volume":"11","author":"Gao","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.08.002_bib127","doi-asserted-by":"crossref","first-page":"S922","DOI":"10.1016\/j.annonc.2023.09.2631","article-title":"1684TiP PARPiPANC: a multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer","volume":"34","author":"Cassier","year":"2023","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.semcancer.2025.08.002_bib128","doi-asserted-by":"crossref","DOI":"10.3390\/cells11193068","article-title":"Pancreatic ductal adenocarcinoma: molecular pathology and predictive biomarkers","volume":"11","author":"Taherian","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.semcancer.2025.08.002_bib129","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113497","article-title":"Precision Medicine for KRAS wild-type pancreatic adenocarcinomas","volume":"197","author":"Ben-Ammar","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib131","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK Fusion-Positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib132","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.semcancer.2025.08.002_bib133","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-19-1280","article-title":"Oncogenic NRG1 fusions: a new hope for targeted therapy in pancreatic cancer","volume":"25","author":"Aguirre","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib134","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41379-019-0373-y","article-title":"RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas","volume":"33","author":"Chou","year":"2020","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib135","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1078-0432.CCR-23-2268","article-title":"An analysis of Dosing-Related postmarketing requirements for novel oncology drugs approved by the U.S. Food and drug administration, 2012-2022","volume":"30","author":"Collins","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib136","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41698-024-00683-x","article-title":"FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer","volume":"8","author":"Stein","year":"2024","journal-title":"NPJ Precis Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib137","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib138","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2023.04.012","article-title":"Efficacy of immune checkpoint inhibitors in microsatellite unstable\/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO european cohort","volume":"188","author":"Ta\u00efeb","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib139","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00535-019-01620-7","article-title":"Microsatellite instability and immune checkpoint inhibitors: toward precision Medicine against gastrointestinal and hepatobiliary cancers","volume":"55","author":"Eso","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib140","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00092","article-title":"Tumor mutational burden in Real-World patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","author":"Quintanilha","year":"2023","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110626","article-title":"Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers","volume":"130","author":"Wang","year":"2020","journal-title":"Biomed. Pharm."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib142","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib143","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2025.08.002_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116733","article-title":"Beyond monotherapy: an era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors","volume":"175","author":"Zhou","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"9","key":"10.1016\/j.semcancer.2025.08.002_bib145","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) t cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.semcancer.2025.08.002_bib146","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.devcel.2023.07.025","article-title":"Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8(+) t cells","volume":"58","author":"Mahadevan","year":"2023","journal-title":"Dev. Cell"},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib147","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11523-020-00727-9","article-title":"Molecular targeting of a BRAF mutation in pancreatic ductal adenocarcinoma: case report and literature review","volume":"15","author":"Seghers","year":"2020","journal-title":"Target Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib148","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1159\/000510096","article-title":"Metastatic pancreatic cancer with BRAF and P53 mutations: case report of therapeutic response to doublet targeted therapy","volume":"13","author":"Sasankan","year":"2020","journal-title":"Case Rep. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib149","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000496018","article-title":"Beyond KRAS: practical molecular targets in pancreatic adenocarcinoma","volume":"12","author":"Grinshpun","year":"2019","journal-title":"Case Rep. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1078-0432.CCR-11-1387","article-title":"A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303","volume":"18","author":"Innocenti","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.semcancer.2025.08.002_bib151","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.4049\/jimmunol.167.8.4137","article-title":"Cutting edge: IL-17F, a novel cytokine selectively expressed in activated t cells and monocytes, regulates angiogenesis and endothelial cell cytokine production","volume":"167","author":"Starnes","year":"2001","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib152","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10875-007-9125-8","article-title":"The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis","volume":"28","author":"Arisawa","year":"2008","journal-title":"J. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib153","first-page":"717","article-title":"Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia","volume":"20","author":"Arisawa","year":"2007","journal-title":"Int J. Mol. Med."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib154","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv387","article-title":"Relevance of sp binding site polymorphism in WWOX for treatment outcome in pancreatic cancer","volume":"108","author":"Schirmer","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"14","key":"10.1016\/j.semcancer.2025.08.002_bib155","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-11-2856","article-title":"A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival","volume":"18","author":"Willis","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5897","key":"10.1016\/j.semcancer.2025.08.002_bib156","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib157","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/gutjnl-2012-303477","article-title":"Genome-wide association study of survival in patients with pancreatic adenocarcinoma","volume":"63","author":"Wu","year":"2014","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.semcancer.2025.08.002_bib158","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/carcin\/bgw080","article-title":"Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients","volume":"37","author":"Rizzato","year":"2016","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib159","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.30762","article-title":"Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study","volume":"141","author":"Tang","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"26","key":"10.1016\/j.semcancer.2025.08.002_bib160","doi-asserted-by":"crossref","first-page":"42537","DOI":"10.18632\/oncotarget.16451","article-title":"RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer","volume":"8","author":"Mao","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib161","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FPC.0b013e32834e9eba","article-title":"A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy","volume":"22","author":"Kiyotani","year":"2012","journal-title":"Pharm. Genom."},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib162","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/FPC.0000000000000375","article-title":"An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)","volume":"29","author":"Innocenti","year":"2019","journal-title":"Pharm. Genom."},{"issue":"19","key":"10.1016\/j.semcancer.2025.08.002_bib163","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-\u03b2 signaling in health and disease","volume":"186","author":"Massagu\u00e9","year":"2023","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.semcancer.2025.08.002_bib164","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/1078-0432.CCR-07-4187","article-title":"MDM2 promoter polymorphism and pancreatic cancer risk and prognosis","volume":"14","author":"Asomaning","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2025.08.002_bib165","article-title":"The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib166","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/annonc\/mdu449","article-title":"A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage","volume":"26","author":"Findlay","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib167","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056918","article-title":"MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis","volume":"8","author":"Ma","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.semcancer.2025.08.002_bib168","article-title":"Genetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib169","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPA.0b013e3181f95104","article-title":"Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma","volume":"40","author":"Grochola","year":"2011","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jso.23826","article-title":"Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: analysis of CD G870A polymorphism, FISH and immunohistochemistry","volume":"111","author":"Bachmann","year":"2015","journal-title":"J. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2025.08.002_bib171","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/apm.12289","article-title":"Cyclin D1, p16(INK) (4A) and p27(Kip1) in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis","volume":"122","author":"Georgiadou","year":"2014","journal-title":"Apmis"},{"issue":"22","key":"10.1016\/j.semcancer.2025.08.002_bib172","doi-asserted-by":"crossref","first-page":"36033","DOI":"10.18632\/oncotarget.16422","article-title":"BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027921","article-title":"Pancreatic cancer susceptibility loci and their role in survival","volume":"6","author":"Rizzato","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semcancer.2025.08.002_bib174","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/MPA.0000000000000263","article-title":"Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival","volume":"44","author":"Smith","year":"2015","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1078-0432.CCR-09-1555","article-title":"Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity","volume":"16","author":"Okazaki","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib176","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/MPA.0000000000001052","article-title":"SLCO1B1 polymorphism is a drug response predictive marker for advanced pancreatic cancer patients treated with gemcitabine, S-1, or gemcitabine plus S-1","volume":"47","author":"Sato","year":"2018","journal-title":"Pancreas"},{"key":"10.1016\/j.semcancer.2025.08.002_bib177","doi-asserted-by":"crossref","DOI":"10.1038\/srep43812","article-title":"SLC22A3 polymorphisms do not modify pancreatic cancer risk, but May influence overall patient survival","volume":"7","author":"Mohelnikova-Duchonova","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib178","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/carcin\/bgz006","article-title":"Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients","volume":"40","author":"Gentiluomo","year":"2019","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib179","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/j.gastro.2023.05.037","article-title":"A fecal MicroRNA signature by small RNA sequencing accurately distinguishes colorectal cancers: results from a multicenter study","volume":"165","author":"Pardini","year":"2023","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.semcancer.2025.08.002_bib180","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2217\/nnm-2017-0054","article-title":"Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells","volume":"12","author":"Schnittert","year":"2017","journal-title":"Nanomedicine"},{"issue":"46","key":"10.1016\/j.semcancer.2025.08.002_bib181","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.3748\/wjg.v28.i46.6478","article-title":"Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer","volume":"28","author":"Watanabe","year":"2022","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib182","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.molonc.2015.11.012","article-title":"Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer","volume":"10","author":"Tjensvoll","year":"2016","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib183","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41598-023-31051-7","article-title":"Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging","volume":"13","author":"Watanabe","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib184","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1038\/s41598-017-08297-z","article-title":"Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer","volume":"7","author":"Del Re","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib185","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1634\/theoncologist.2017-0467","article-title":"Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring","volume":"23","author":"Perets","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib186","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-1298","article-title":"Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating Cell-Free DNA in pancreatic cancer","volume":"18","author":"Wei","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"3_","key":"10.1016\/j.semcancer.2025.08.002_bib187","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.2021.39.3_suppl.423","article-title":"Serial cell-free DNA (cfDNA) sampling in advanced pancreatic ductal adenocarcinoma (PDAC) patients May predict therapeutic outcome","volume":"39","author":"Botrus","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.semcancer.2025.08.002_bib188","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010902","article-title":"Serum miR-373-3p and miR-194-5p are associated with early tumor progression during FOLFIRINOX treatment in pancreatic cancer patients: a prospective multicenter study","volume":"22","author":"van der Sijde","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.08.002_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103166","article-title":"The main sources of circulating cell-free DNA: apoptosis, necrosis and active secretion","volume":"157","author":"Hu","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031640","article-title":"Clinical application of liquid biopsy in pancreatic cancer: a narrative review","volume":"25","author":"Ram\u00edrez-Maldonado","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.semcancer.2025.08.002_bib191","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/clinchem\/hvac153","article-title":"Parallel analysis of Pre- and postoperative circulating tumor DNA and matched tumor tissues in resectable pancreatic ductal adenocarcinoma: a prospective cohort study","volume":"68","author":"Lee","year":"2022","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.semcancer.2025.08.002_bib192","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41416-019-0704-2","article-title":"Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients","volume":"122","author":"Guo","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2025.08.002_bib193","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib194","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/clinchem\/hvac214","article-title":"Peripheral and portal venous KRAS ctDNA detection as independent prognostic markers of early tumor recurrence in pancreatic ductal adenocarcinoma","volume":"69","author":"Nitschke","year":"2023","journal-title":"Clin. Chem."},{"issue":"9","key":"10.1016\/j.semcancer.2025.08.002_bib195","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","article-title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.08.002_bib196","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1245\/s10434-021-10985-0","article-title":"Circulating tumor DNA as a potential prognostic marker in patients with Borderline-Resectable pancreatic cancer undergoing neoadjuvant chemotherapy followed by pancreatectomy","volume":"29","author":"Kitahata","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.semcancer.2025.08.002_bib197","article-title":"Circulating Cell-Free tumor DNA in advanced pancreatic adenocarcinoma identifies patients with worse overall survival","volume":"11","author":"Botrus","year":"2021","journal-title":"Front Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.08.002_bib198","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.dld.2023.03.011","article-title":"Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: the KRASCIPANC prospective study","volume":"55","author":"Evrard","year":"2023","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib199","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2018.09.022","article-title":"Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer","volume":"156","author":"Bernard","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib200","article-title":"Preliminary investigation of the efficacy and indications of proton beam therapy for stage IV pancreatic adenocarcinoma","volume":"16","author":"Yamaguchi","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.semcancer.2025.08.002_bib201","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/oncolo\/oyac179","article-title":"KRAS mutation variants and Co-occurring PI3K pathway alterations impact survival for patients with pancreatic ductal adenocarcinomas","volume":"27","author":"Diehl","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.semcancer.2025.08.002_bib202","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4143\/crt.2023.452","article-title":"Analysis of plasma circulating tumor DNA in borderline resectable pancreatic cancer treated with neoadjuvant modified FOLFIRINOX: clinical relevance of DNA damage repair gene alteration detection","volume":"55","author":"Lim","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.semcancer.2025.08.002_bib203","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.pan.2023.05.003","article-title":"Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocarcinoma","volume":"23","author":"Stubbe","year":"2023","journal-title":"Pancreatology"},{"key":"10.1016\/j.semcancer.2025.08.002_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.148078","article-title":"Clinical significance of tumor suppressor genes methylation in circulating tumor DNA of patients with pancreatic cancer","volume":"897","author":"Xin","year":"2024","journal-title":"Gene"},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071612","article-title":"Somatic mutation profiling in the liquid biopsy and clinical analysis of hereditary and familial pancreatic cancer cases reveals KRAS negativity and a longer overall survival","volume":"13","author":"Earl","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.semcancer.2025.08.002_bib206","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071754","article-title":"Circulating Cell-Free DNA-Based liquid biopsy markers for the Non-Invasive prognosis and monitoring of metastatic pancreatic cancer","volume":"12","author":"Toledano-Fonseca","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semcancer.2025.08.002_bib207","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12967-018-1677-2","article-title":"Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer","volume":"16","author":"Lapin","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.semcancer.2025.08.002_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103548","article-title":"Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: a systematic review and meta-analysis","volume":"169","author":"Bunduc","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X25001105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:50:40Z","timestamp":1772880640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X25001105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":208,"alternative-id":["S1044579X25001105"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.08.002","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic pancreatic cancer biomarkers and pharmacogenetics","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}